Bayer Shares Jump After Drug Candidate Shows Stroke Prevention Potential

• Bayer's shares experienced a significant increase following the announcement that asundexian, when used in conjunction with antiplatelet therapy, demonstrated a reduced risk of stroke in patients during clinical trials.
• This development is crucial for Bayer as it highlights the potential of asundexian as a viable treatment option, potentially enhancing the company's portfolio in the health sector and improving patient outcomes in stroke prevention.

— via World Pulse Now AI Editorial System